Ferdinandos Skoulidis summarizes why the development of KRAS^G12C targeted therapies failed in the past, relates to new developments in the field of KRAS^G12C inhibition especially sotorasib and discusses the impact of co-mutations on personalized anticancer therapy.

Here is the full ASCO 2021 report.